廣告
香港股市 將在 4 小時 33 分鐘 開市
  • 恒指

    16,828.93
    +317.24 (+1.92%)
     
  • 國指

    5,954.62
    +123.36 (+2.12%)
     
  • 上證綜指

    3,021.98
    -22.62 (-0.74%)
     
  • 道指

    38,503.69
    +263.71 (+0.69%)
     
  • 標普 500

    5,070.55
    +59.95 (+1.20%)
     
  • 納指

    15,696.64
    +245.33 (+1.59%)
     
  • Vix指數

    15.69
    -1.25 (-7.38%)
     
  • 富時100

    8,044.81
    +20.94 (+0.26%)
     
  • 紐約期油

    83.34
    +1.44 (+1.76%)
     
  • 金價

    2,335.80
    -10.60 (-0.45%)
     
  • 美元

    7.8347
    -0.0010 (-0.01%)
     
  • 人民幣

    0.9242
    +0.0004 (+0.04%)
     
  • 日圓

    0.0503
    -0.0000 (-0.02%)
     
  • 歐元

    8.3843
    +0.0383 (+0.46%)
     
  • Bitcoin

    66,255.69
    -204.20 (-0.31%)
     
  • CMC Crypto 200

    1,427.04
    +12.28 (+0.87%)
     

Rain Therapeutics Experimental Cancer Therapy Shows Encouraging Tumor Regression Activity

  • Rain Therapeutics Inc (NASDAQ: RAIN) announced preliminary data from Phase 2 basket trial evaluating milademetan for MDM2-amplified advanced solid tumors.

  • "Treatment with milademetan led to tumor regression in patients previously treated with a multitude of therapies across a range of cancers. We look forward to expanding this dataset as the trial continues to enroll," said Avanish Vellanki, co-founder & CEO.

  • Seventeen patients have been enrolled, 15 of whom have been dosed with milademetan. Ten patients were efficacy-evaluable.

  • Two unconfirmed partial responses (PRs) were observed with tumor regression of 34% and 30% (pancreatic and lung cancer, respectively).

  • Related: This Cancer-Focused Stock Has 60% Potential Upside, Bullish Analyst Says.

  • Two patients exhibited promising activity with tumor regression of 29% and 27% (biliary tract and breast cancer, respectively), and the patients are continuing with the investigational therapy.

  • Safety profile to date is preliminarily consistent with prior Phase 1 trial of milademetan

  • Concurrently, Rain Therapeutics priced a registered offering of 6.86 million shares and 1.72 million non-voting shares at $5.83 per share, with gross proceeds of approximately $50 million.

  • Price Action: RAIN shares are up 2.92% at $6.00 on the last check Friday.

See more from Benzinga

廣告

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.